Drug Profile
Silmitasertib - Senhwa Biosciences
Alternative Names: CX 4945Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Cylene Pharmaceuticals
- Developer Cylene Pharmaceuticals; Penn State College of Medicine; Senhwa Biosciences; Stanford University School of Medicine
- Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Carboxylic acids; Naphthyridines; Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia; COVID 2019 infections
- Phase I/II Cholangiocarcinoma; Medulloblastoma
- Phase I Basal cell cancer
- Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Giant lymph node hyperplasia; Multiple myeloma; Solid tumours
Most Recent Events
- 20 Mar 2024 Phase-II clinical trials in Community-acquired pneumonia (Combination therapy) in Taiwan (PO) (NCT06202521)
- 08 Mar 2024 Pediatric Brain Tumor Consortium suspends phase I/II clinical trial in Medulloblastoma (Second-line therapy or greater, Recurrent, In adolescents, In adults, In children, In the elderly) in USA (PO) due to drug supply issues(NCT03904862)
- 26 Dec 2023 Taiwan FDA approves IND application for Silmitasertib in Community-acquired pneumonia